- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 28.04. | Spruce halves head count, narrowing focus to get ex-BioMarin drug to FDA | ||
| 28.04. | Pfizer ties PD-1 drug to 32% bladder cancer risk reduction in mixed bag phase 3 as it misses secondaries | ||
| 25.04. | ALX Oncology doubles down on lead CD47 inhibitor after asset fails two midstage cancer trials | ||
| 25.04. | M&A remains 'top priority' for Big Pharmas in the face of tariff threat | ||
| 25.04. | FDA puts Vyne in a twist, slapping hold on psoriasis trial over testicular toxicity concerns | ||
| 24.04. | Ex-FDA leader joins new initiative designed to fight 'unfortunate reality' of vaccine landscape | ||
| 24.04. | Mosaic Therapeutics adds to cancer combo pattern by licensing 2 clinical-stage drugs from Astex | ||
| 24.04. | Bioxodes halts phase 2 stroke trial after successful interim review, plots registrational study | ||
| 24.04. | Tariffs will make financial case for pharma M&A 'more difficult,' says Roche CEO | ||
| 24.04. | Sanofi's oral TNF inhibitor misses mark in phase 2 psoriasis trial, prompting focus on combos | ||
| 23.04. | Vanda sues FDA over hearing delay as agency points to mass layoffs, other litigation with the biopharma | ||
| 23.04. | Tempus AI in line for $200M from AstraZeneca, Pathos deal to develop cancer model | ||
| 23.04. | German cancer antibody biotech eyes SPAC as route to Nasdaq | ||
| 23.04. | Boehringer inks Tessellate deal to slot synthetic lethal program into oncology pipeline | ||
| 23.04. | Ascletis sees no benefit to high, fast oral GLP-1 dose titration, takes low, slow regimen forward | ||
| 23.04. | Sanofi hands back cancer NK cell engager to Innate amid autoimmune pivot | ||
| 22.04. | 'Severe consequences of government overreach': Harvard sues Trump admin over funding freeze | ||
| 22.04. | Roche looks to 'expand and upgrade' US research centers as part of $50B investment strategy in the country | ||
| 21.04. | As Harvard battle escalates, HHS directs NIH not to tell universities about new grant freezes: reports | ||
| 21.04. | Brexit-related costs leave UK cancer patients, research in jeopardy: report | ||
| 21.04. | Immunovant narrows R&D focus as Roivant execs take CEO, CFO posts | ||
| 21.04. | Tempest lays off 80% of workforce to ride out cash crunch | ||
| 18.04. | Alis offers exit option to biotechs tainted by tang of failure, providing way to return cash to shareholders | ||
| 18.04. | NIH nixes support for Pluri's radiation exposure cell therapy amid cost-cutting drive | ||
| 18.04. | Stealth biotech bags rights to VelaVigo bispecific in $440M deal |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .